Iksuda’s IKS03 Shows 53% Response Rate in Early-Stage B-Cell Lymphoma Trial
Iksuda Therapeutics reported a 53% response rate for IKS03 in an early-stage B-cell lymphoma trial.
Related stories
Canadian Natural Resources Beats Quarterly Profit Estimate
M impact | EQUITY | Nov 05, 2026, 09:47 AM UTC
Insecticides (India) Q2 Consolidated Net Profit INR 561.7 Million
M impact | EQUITY | Nov 05, 2026, 09:45 AM UTC
Shanghai International Port Expects October Container Throughput Up 9.8%
The company also expects cargo throughput to rise 5.6% year over year.
L impact | EQUITY | Nov 05, 2026, 09:45 AM UTC
SiTime shares rise 4.2% premarket after Q3 revenue beats estimates
M impact | EQUITY | Nov 05, 2026, 09:44 AM UTC
Toyota Raises 2027 EPS Outlook as Fiscal Q2 Revenue Rises
Toyota's fiscal second-quarter revenue rose, and it raised its 2027 EPS outlook. Shares jumped before the bell.
M impact | EQUITY | Nov 05, 2026, 09:43 AM UTC
CERT-In Flags Vulnerabilities in Tata Motors’ iRA Apps
India’s CERT-In warned that vulnerabilities in Tata Motors’ iRA 2.0 and iRA.ev apps could be exploited to extract embedded sensitive information.
M impact | EQUITY | Nov 05, 2026, 09:43 AM UTC